30 October 2023 - A special test that predicts the chance of hormone-sensitive breast cancer returning will be added to ...
2 October 2023 - The Swedish Dental and Medicines Benefits Agency, TLV, today submits a report to the government on how ...
31 March 2023 - The TLV has submitted an interim report to the government for the task of proposing how ...
28 March 2023 - The TLV has clarified the subsidy limitation for all GLP-1 receptor agonists. ...
21 November 2022 - Paxlovid, which treats patients who are at risk of becoming seriously ill from COVID-19, will be ...
18 November 2022 - The Dental and Pharmaceutical Benefits Agency, TLV, has decided that the drugs Kaftrio, Kalydeco and Symkevi, ...
8 June 2022 - Since April 2022, Verzenios has had market approval for the treatment of adult patients with early breast ...
2 June 2022 - The TLV has started a trial for the interleukin 17 and interleukin 23 inhibitors. ...
16 May 2022 - TLV has decided that Tepmetko (tepotinib) shall be included in the high-cost protection until the ordinary subsidy ...
8 September 2021 - Suboxone is among the medicines that will be withdrawn from the drug benefits at the companies' ...
10 August 2021 - Faslodex is among the medicines being withdrawn from the drug benefits on 1 September 2021. ...
30 April 2021 - Today, eleven subcutaneous TNF-alpha inhibitors are included in the high-cost protection. ...
18 December 2020 - During the autumn, the Swedish Dental and Pharmaceutical Benefits Agency, TLV, reconsidered the subsidy of the hepatitis ...
23 October 2020 - For the first time in Sweden, a cancer drug against a specific genetic change, instead of against ...
29 September 2020 - Liraglutide (Saxenda), which is intended for weight control in adult patients with obesity or are overweight, ...